J. Booij et al., [I-123] FP-CIT SPECT SHOWS A PRONOUNCED DECLINE OF STRIATAL DOPAMINE TRANSPORTER LABELING IN EARLY AND ADVANCED PARKINSONS-DISEASE, Journal of Neurology, Neurosurgery and Psychiatry, 62(2), 1997, pp. 133-140
Objectives-The main neuropathological feature in Parkinson's disease i
s a severe degeneration of the dopaminergic neurons in the substantia
nigra resulting in a loss of dopamine (DA) transporters in the striatu
m. [I-123]beta-CIT single photon emission computed tomography (SPECT)
studies have demonstrated this loss of striatal DA transporter content
in Parkinson's disease in vivo. However, studies with this radioligan
d also showed that an adequate imaging of the striatal DA transporter
content could only be performed on the day after the injection of radi
oligand, which is not convenient for outpatient evaluations. Recently,
a new radioligand [I-123]FP-CIT, with faster kinetics than beta-CIT,
became available for imaging of the DA transporter with SPECT, and the
applicability of this ligand was tested in patients with early and ad
vanced Parkinson's disease, using a one day protocol. Methods-[I-123]F
P-CIT SPECT was performed in six patients with early and 12 patients w
ith advanced Parkinson's disease, and in six age matched healthy volun
teers. Results-Compared with an age matched control group striatal [I-
123]FP-CIT uptake in patients with Parkinson's disease was Neurology,
decreased, and this result was measurable three hours after injection
of the radioligand. In the Parkinson's disease group the uptake in the
putamen was reduced more than in the caudate nucleus. The contralater
al striatal uptake of [I-123]FP, CIT was significantly lower than the
ipsilateral striatal uptake in the Parkinson's disease group. Specific
to non-specific striatal uptake ratios correlated with the Hoehn and
Yahr stage. A subgroup of patients with early Parkinson's disease also
showed significantly lower uptake in the putamen and lower putamen:ca
udate ratios than controls. Conclusion-[I-123]FP-CIT SPECT allows a si
gnificant discrimination between patients with Parkinson's disease and
age matched controls with a one day protocol, which will be to great
advantage in outpatient evaluations.